title: Transitioning to and from the novel oral anticoagulants: a management strategy for clinicians.
abstract: Vitamin K antagonists have been the only available oral anticoagulant therapy for decades until the recent introduction of novel (new) oral anticoagulants. This breakthrough provides patients with alternative treatment choices that have predictable pharmacokinetics and do not require routine coagulation monitoring. Though more convenient from patient perspective, these drugs have distinct pharmacological properties that are particularly important to recognize when transitioning anticoagulant therapies. The following review focuses on transitioning to and from the novel oral anticoagulants, employing a practical pharmacokinetic- and pharmacodynamic-based approach.
authors: Division of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, University of Cincinnati, 231 Albert Sabin Way, Room 3461 MSB, PO Box 670542, Cincinnati, OH, 45267-0542, USA, abosaled@ucmail.uc.edu.
authors: Elsayed
authors: E
authors: Abo-Salem
authors: Richard
authors: R
authors: Becker
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects; D006801:Humans; D008991:Monitoring, Physiologic / Q000379:methods*; D014812:Vitamin K / Q000037:antagonists & inhibitors*
chemical_list: D000925:Anticoagulants; D014812:Vitamin K